Piper Sandler reiterates Regeneron stock rating on anti-VEGF shift By Investing.com

The key read-through is not just incremental REGN upside, but a potential industry-level mix shift from commodity-like bevacizumab usage toward branded anti-VEGF pricing power. If community retina clinics are truly being squeezed on Avastin margins, the next leg of the trade is a volume reallocation that benefits the highest-trust branded franchises first, not necessarily the broadest basket of names. That creates asymmetric leverage for the incumbent with the strongest payer access and physician habit persistence, while also implying a smaller but real halo for adjacent branded ophthalmology suppliers.

The market is probably underestimating the duration of the transition. Once clinics retool workflows and billing around branded treatments, switching back is operationally hard, which makes the shift sticky over multiple quarters rather than a one-off quarter. The second-order effect is a widening moat for the branded leaders and a slower-than-expected erosion of pricing even if payer pushback intensifies, because the clinic economics—not just efficacy—appear to be driving adoption.

Near term, the main risk is that management commentary or payer interventions frame this as a temporary inventory or reimbursement artifact, which would compress the rerating quickly. The cleaner catalyst window is the upcoming earnings print and then the next 1-2 quarters of retina prescription data; if share gains are visible, sell-side targets likely move higher again. For TLX, the read-through is more selective: the partnership validates strategic optionality, but the stock only works if the market starts capitalizing platform value rather than treating collaborations as non-core.

Contrarianly, the consensus may be too focused on absolute upside to REGN and not enough on the broader category expansion. If Avastin share falls faster than expected, the biggest surprise could be that the pie grows through better reimbursement economics, allowing multiple branded participants to win simultaneously. The stock-specific opportunity is still best in REGN, but the broader trade is a relative-value long on branded anti-VEGF exposure versus any basket tied to low-margin off-label utilization.